Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) ...
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
Zacks.com on MSN1d
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...
Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...
With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy ...
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...
Vertex Pharmaceuticals ... to allow patients with sickle cell disease (SCD) to access its gene-edited therapy Casgevy, developed with CRISPR Therapeutics (NASDAQ:CRSP). The deal comes after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback